BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31843555)

  • 1. Androgen receptor suppresses prostate cancer metastasis but promotes bladder cancer metastasis via differentially altering miRNA525-5p/SLPI-mediated vasculogenic mimicry formation.
    Yang Z; Chen J; Xie H; Liu T; Chen Y; Ma Z; Pei X; Yang W; Li L
    Cancer Lett; 2020 Mar; 473():118-129. PubMed ID: 31843555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
    Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
    Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor suppresses vasculogenic mimicry in hepatocellular carcinoma via circRNA7/miRNA7-5p/VE-cadherin/Notch4 signalling.
    Bao S; Jin S; Wang C; Tu P; Hu K; Lu J
    J Cell Mol Med; 2020 Dec; 24(23):14110-14120. PubMed ID: 33118329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
    Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
    Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals.
    Ou Z; Wang Y; Liu L; Li L; Yeh S; Qi L; Chang C
    Oncotarget; 2015 Sep; 6(28):26065-78. PubMed ID: 26305549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Androgen Receptor Signaling Promotes Prostate Cancer Cell Migration via Upregulation of Annexin A1 Expression.
    Yang W; Wang K; Ma J; Hui K; Lv W; Ma Z; Huan M; Luo L; Wang X; Li L; Chen Y
    Arch Med Res; 2021 Feb; 52(2):174-181. PubMed ID: 33059953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor suppresses prostate cancer cell invasion via altering the miR-4496/β-catenin signals.
    Wang RF; Wang ZF; Cheng Q; Wang GR; Bai ZM
    Biochem Biophys Res Commun; 2018 Sep; 504(1):82-88. PubMed ID: 30177389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.
    Hu S; Li L; Yeh S; Cui Y; Li X; Chang HC; Jin J; Chang C
    Mol Oncol; 2015 Jan; 9(1):44-57. PubMed ID: 25135278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7.
    Chen W; Yao G; Zhou K
    J Cell Biochem; 2019 Aug; 120(8):14055-14064. PubMed ID: 30963631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
    Chen J; Li L; Yang Z; Luo J; Yeh S; Chang C
    Cancer Lett; 2017 Nov; 408():155-163. PubMed ID: 28826721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR.
    You B; Sun Y; Luo J; Wang K; Liu Q; Fang R; Liu B; Chou F; Wang R; Meng J; Huang CP; Yeh S; Chang C; Xu W
    Oncogene; 2021 Mar; 40(9):1674-1689. PubMed ID: 33510354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
    Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR.
    Zheng L; Kang Y; Zhang L; Zou W
    Cancer Biol Ther; 2020; 21(1):34-42. PubMed ID: 31736422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
    Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
    PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells.
    Gong AY; Eischeid AN; Xiao J; Zhao J; Chen D; Wang ZY; Young CY; Chen XM
    BMC Cancer; 2012 Oct; 12():492. PubMed ID: 23095762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling.
    Wang ZC; Li Y; Wang KL; Wang L; You BS; Zhao DF; Liu ZQ; Fang RZ; Wang JQ; Zhang W; Zhang JM; Xu WH
    Aging (Albany NY); 2020 Jul; 12(14):14418-14433. PubMed ID: 32694237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
    Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.